Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer

Abstract

We wish to correct a number of figure-related and typographical errors that appeared in the article above. None of these errors affect the conclusions of the paper.In Figures 2F and S5 (upper-right), we presented two phase-contrast photos of fields of cells, correctly labeled as SCNT-derived hESO-NT1 and IVF-derived hESO-7, respectively. These images are the same fields of cells shown in the top two images of Figure 6D; however, in Figure 6D, we inadvertently switched the labels on the images. This re-use of the images was intentional, but we should have indicated this in the original legend for Figure 6. We have corrected the labeling error in Figure 6D.In Figure S6, the scatterplot presenting a comparison between biological HDF-f replicates #2 and #3 is an inadvertent duplication of the scatterplot presenting the comparison of HDF-f replicates #1 and #3. This plot has been replaced in the figure online and is shown below.In Figure 1, the number of SCNT embryos for I/DMAP group (n = 51) has been corrected to 53.In Figure 5D, the numbers of plated blastocysts for agonist and antagonist were reversed and have been corrected to agonist (n = 4) and antagonist (n = 17).In the Experimental Procedures, the age range of oocyte donors in the paper was listed as 23-31; however, the range has been corrected to 23-33.In Table S2, percentages for fused oocytes in the 10 nM TSA for 24 hr group (95.4) and for compact morula (CM) in the 5 nM TSA for 12 hr group (26.0) have been corrected to 96.3 and 28.0, respectively.In Table S3, we incorrectly reported several figures due to errors that occurred in converting the raw patient data, from which these values are calculated, from a file created with Mac-based software to a file in the analogous Windows-based software. The following corrections have been made: number of oocytes in the antagonist group 11.7 ± 5.6 has been changed to 10.2 ± 4.9; number of oocytes in the agonist group, 20.5 ± 11.9 to 16.3 ± 5.2; AMH level in the antagonist group, 2.8 ± 0.5 to 2.5 ± 0.5; AFC in the antagonist group, 23.1 ± 7.2 to 23.2 ± 7.2; FSH dosage in antagonist group, 958.3 ± 241.7 to 966.7 ± 247.3; number of hMG ampoules in antagonist group, 8.5 ± 1.6 to 10.2 ± 4.2; number of hMG ampoules in agonist group, 8.8 ± 0.9 to 8.8 ± 1.0; stimulation days in antagonist group, 8.7 ± 1.6 to 8.7 ± 0.8; and stimulation days in agonist group, 9 ± 0.8 to 9.8 ± 1.0. We have confirmed that these differences do not affect any of the statistical conclusions originally reported.In Table S4, short tandem repeats (STR) readings for egg donor A in D6S291 and D6S276 loci were reversed and have been corrected to 199/209 for D6S291 and 245/249 for D6S276.

Functional Human Oocytes Generated by Transfer of Polar Body Genomes

“…Research gamete donors were financially compensated for their time, effort, discomfort, and inconvenience associated with the donation process at rates similar to donors whose gametes were used for reproductive purposes. This specific IRB protocol was first approved in 2011 and then reviewed annually with modifications allowing the development, evaluation and testing, in vitro, of novel mitochondrial replacement techniques (see Data S1) (Kang et al, 2016;Ma et al, 2015;Tachibana et al, 2013a;Tachibana et al, 2013b).…”

“…We previously demonstrated that interphase nuclei of skin fibroblasts transplanted into enucleated human MII oocytes (cytoplasts) undergo rapid remodeling and cell cycle reprogramming resulting in the formation of oocyte-like MII-arrested spindles Tachibana et al, 2013a). We determined that the residual meiotic activity in cytoplasts capable of forming de novo MII spindles is critical for reprogramming and subsequent embryonic development following somatic cell nuclear transfer (SCNT).…”

The ups and downs of somatic cell nucleus transfer (SCNT) in humans

“…The very recent paper published by Mitalipov's groups confirmed that this is true [5]. In these experiments the oocytes from paid donors were used and some minor, but probably very essential modifications, were introduced into their NT scheme.…”

“…In fact, both these treatments were already used in animal NT experiments and improved their efficiency [9]. In general, the NT scheme has been perfected in previous experiments performed by this group and some other technical details can be found in a given paper [5]. Taken together, the efficiency of a given NT scheme was quite high and this was confirmed by a very good embryonic development and high efficiency when ESC lines were established from them.…”

Generation of fertile offspring from Kitw/Kitwv mice through differentiation of gene corrected nuclear transfer embryonic stem cells

“…The two major approaches, somatic cell nuclear transfer (SCNT) and reprogramming of somatic cells into induced PSCs (iPSCs), have been successfully applied to mouse and human cells [12][13][14][15]. There have been reports on successful rescue of disease phenotypes in some mouse models, such as mice carrying mutations in Crygc [16], Lrrk2 [17], and Bcl11a [18], by combing somatic cell reprogramming and gene correction technologies.…”